{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:05:33Z","timestamp":1771560333817,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T00:00:00Z","timestamp":1413590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00228-014-1772-0","type":"journal-article","created":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T01:48:21Z","timestamp":1413510501000},"page":"1471-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clozapine serum concentrations in dopamimetic psychosis in Parkinson\u2019s disease and related disorders"],"prefix":"10.1007","volume":"70","author":[{"given":"Ulrich C.","family":"Lutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Sirfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Wiatr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"Altpa\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisbert","family":"Farger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin N.","family":"Karle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Batra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,18]]},"reference":[{"key":"1772_CR1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","volume":"15","author":"S Campenhausen Von","year":"2005","unstructured":"Von Campenhausen S, Bornschein B, Wick R, B\u00f6tzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson\u2019s disease in Europe. Eur Neuropsychopharmacol 15:473\u2013490","journal-title":"Eur Neuropsychopharmacol"},{"key":"1772_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2010.05.004","volume":"16","author":"JH Friedman","year":"2010","unstructured":"Friedman JH (2010) Parkinson\u2019s disease psychosis 2010: a review article. Parkinsonism Relat Disord 16:553\u2013560","journal-title":"Parkinsonism Relat Disord"},{"key":"1772_CR3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","volume":"60","author":"SA Factor","year":"2003","unstructured":"Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, The Parkinson Study Group (2003) Longitudinal outcome of Parkinson\u2019s disease patients with psychosis. Neurology 60:1756\u20131761","journal-title":"Neurology"},{"key":"1772_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","volume":"27","author":"L Morgante","year":"2004","unstructured":"Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27:153\u2013156","journal-title":"Clin Neuropharmacol"},{"key":"1772_CR5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Dest\u00e9e A, P\u00e9r\u00e9 JJ, Senard JM, Durif F, Bourdeix I (2004) Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiat 75:689\u2013695","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"1772_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","volume":"17","author":"H Frieling","year":"2007","unstructured":"Frieling H, Hillemacher T, Ziegenbein M, Neund\u00f6rfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson\u2019s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165\u2013171","journal-title":"Eur Neuropsychopharmacol"},{"key":"1772_CR7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","volume":"48","author":"JH Friedman","year":"1997","unstructured":"Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease. Neurology 48:1077\u20131081","journal-title":"Neurology"},{"key":"1772_CR8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiatry 52:438\u2013445","journal-title":"Biol Psychiatry"},{"key":"1772_CR9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","volume":"45","author":"J Zoldan","year":"1995","unstructured":"Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson\u2019s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305\u20131308","journal-title":"Neurology"},{"key":"1772_CR10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 35:881\u2013892","journal-title":"Neuropsychopharmacology"},{"key":"1772_CR11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","volume":"7","author":"P Gareri","year":"2008","unstructured":"Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G (2008) The safety of clozapine in the elderly. Expert Opin Drug Saf 7:525\u2013538","journal-title":"Expert Opin Drug Saf"},{"key":"1772_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","volume":"21","author":"I Gaertner","year":"2001","unstructured":"Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21:305\u2013310","journal-title":"J Clin Psychopharmacol"},{"key":"1772_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, M\u00fcller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"1772_CR14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","volume":"83","author":"YQ Xiang","year":"2006","unstructured":"Xiang YQ, Zhang ZJ, Wenig YZ, Zhai YM, Li WB, Cai ZJ, Tan QR, Wang CY (2006) Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 83:201\u2013210","journal-title":"Schizophr Res"},{"key":"1772_CR15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","volume":"32","author":"L Couchman","year":"2010","unstructured":"Couchman L, Morgan PE, Spencer EP, Flanagan RJ (2010) Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 32:438\u2013447","journal-title":"Ther Drug Monit"},{"key":"1772_CR16","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1007\/BF00442557","volume":"99","author":"C Haring","year":"1989","unstructured":"Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H (1989) Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacol (Berl) 99:S38\u2013S40","journal-title":"Psychopharmacol (Berl)"},{"key":"1772_CR17","first-page":"116","volume":"96","author":"MA Stratton","year":"2003","unstructured":"Stratton MA, Salinas RC (2003) Medication management in the elderly. J Okla State Med Assoc 96:116\u2013122","journal-title":"J Okla State Med Assoc"},{"key":"1772_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00002018-200629080-00009","volume":"29","author":"H Buurma","year":"2006","unstructured":"Buurma H, De Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 29:723\u2013732","journal-title":"Drug Saf"},{"key":"1772_CR19","first-page":"39","volume":"12","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson\u2019s disease. a high potency effect of clozapine. Neuropsychopharmacology 12:39\u201345","journal-title":"Neuropsychopharmacology"},{"key":"1772_CR20","first-page":"77","volume":"2","author":"I Stevens","year":"1995","unstructured":"Stevens I, Mahal A, Gaertner HJ (1995) Clozapin-plasmaspiegel bei der akuttherapie von schizophrenen patienten. Klinische Bedeutung Psychopharmakotherapie 2:77\u201381","journal-title":"Klinische Bedeutung Psychopharmakotherapie"},{"key":"1772_CR21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-200106000-00010","volume":"21","author":"I Gaertner","year":"2001","unstructured":"Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21:305\u2013310","journal-title":"J Clin Psychopharmacol"},{"key":"1772_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e3181c47168","volume":"33","author":"AA Thomas","year":"2010","unstructured":"Thomas AA, Friedman JH (2010) Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 33:14\u201316","journal-title":"Clin Neuropharmacol"},{"key":"1772_CR23","first-page":"1156","volume":"26","author":"M Ackenheil","year":"1976","unstructured":"Ackenheil M, Br\u00e4u H, Burkhart A, Franke A, Pacha W (1976) Antipsychotic efficacy in relation to plasma levels of clozapine (author\u2019s transl). Arzneimittelforschung 26:1156\u20131158","journal-title":"Arzneimittelforschung"},{"key":"1772_CR24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0278-5846(01)00291-3","volume":"26","author":"L Palego","year":"2002","unstructured":"Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano GB, Lucacchini A, Martini C, Dell\u2019Osso L (2002) Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 26:473\u2013480","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1772_CR25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA (2010) Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17:571\u2013584","journal-title":"Curr Med Chem"},{"key":"1772_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","volume":"29","author":"E Jaquenoud Sirot","year":"2009","unstructured":"Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319\u2013326","journal-title":"J Clin Psychopharmacol"},{"key":"1772_CR27","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/00912709922008560","volume":"39","author":"BG Pollock","year":"1999","unstructured":"Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, Condifer KA (1999) Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39:936\u2013940","journal-title":"J Clin Pharmacol"},{"key":"1772_CR28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/dmd.110.035766","volume":"39","author":"AA Walker","year":"2011","unstructured":"Walker AA, Dickmann L, Isoherranen N (2011) Pregnancy decreases rat CYP1A2 activity and expression. Drug Metab Dispos 39:4\u20137","journal-title":"Drug Metab Dispos"},{"key":"1772_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","volume":"41","author":"N Isoherranen","year":"2013","unstructured":"Isoherranen N, Thummel KE (2013) Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 41:256\u2013262","journal-title":"Drug Metab Dispos"},{"key":"1772_CR30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1772-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1772-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1772-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T08:33:17Z","timestamp":1565944397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1772-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,18]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1772-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,18]]}}}